digifab digoxin-specific antibody fragment f(ab) (ovine) 40mg powder for injection vial
phebra pty ltd - digoxin-specific antibody fragment f(ab) (ovine), quantity: 40 mg - injection, powder for - excipient ingredients: mannitol; sodium acetate - digoxin-specific antibody fragment f(ab) (ovine) digifab is indicated for the treatment of known (or strongly suspected) life-threatening digoxin toxicity associated with ventricular arrhythmias, progressive bradycardia, or second or third degree heart block not responsive to atropine, and where additional measures besides withdrawal of digoxin and correction of serum electrolyte abnormalities are considered necessary. consequences of multiple dosing with digifab have not been evaluated.
sandimmun concentrate for infusion
novartis israel ltd - ciclosporin - solution for infusion - ciclosporin 50 mg/ml - cyclosporin - cyclosporin - prophylaxis of organ rejection in kidney liver heart allogenic transplants in conjunction with corticosteroids. may also be used in the treatment of chronic rejection in patients previously treated with other immuno-suppressive agents. bone marrow transplantation.
digoxin 500micrograms/2ml solution for infusion ampoules
a a h pharmaceuticals ltd - digoxin - solution for infusion - 250microgram/1ml
digoxin 500micrograms/2ml solution for infusion ampoules
aspen pharma trading ltd - digoxin - solution for infusion - 250microgram/1ml
digoxin kern pharma 0.25 mg
trima israel pharmaceutical products maabarot ltd - digoxin - tablets - digoxin 0.25 mg - digoxin - cardiac failure:digoxin kern pharma is indicated for the treatment of chronic cardiac failure where the principal cause is systolic dysfunction. the greatest therapeutic benefit is achieved in patients with ventricular dilatation.digoxin kern pharma is specifically indicated where cardiac failure is accompanied by atrial fibrilation.supraventricular arrhythmias:digoxin kern pharma is indicated for the treatment of certain supraventricular arrhythmias, particularly atrial fibrillation and flutter, where its principal beneficial effect is to reduce the ventricular rate.
digoxin-zori
teva pharmaceutical industries ltd, israel - digoxin - tablets - digoxin 0.25 mg - digoxin - digoxin - congestive heart failure (chf), atrial fibrillation, atrial flutter, supraventricular tachycardia.
digoxin solution
atlantic biologicals corps - digoxin (unii: 73k4184t59) (digoxin - unii:73k4184t59) - digoxin 0.05 mg in 1 ml - digoxin oral solution, usp is indicated for the treatment of mild to moderate heart failure. digoxin increases left ventricular ejection fraction and improves heart failure symptoms as evidenced by increased exercise capacity and decreased heart failure-related hospitalizations and emergency care, while having no effect on mortality. where possible, digoxin should be used with a diuretic and an angiotensin-converting enzyme inhibitor, but an optimal order for starting these three drugs cannot be specified. digoxin increases myocardial contractility in pediatric patients with heart failure. digoxin oral solution, usp is indicated for the control of resting ventricular response rate in patients with chronic atrial fibrillation. digoxin should not be used for the treatment of multifocal atrial tachycardia. allergy to digoxin is rare. digoxin is contraindicated in patients with a known hypersensitivity to digoxin or other forms of digitalis. digitalis glycosides, such as digoxin, are contraindicated in ventricula
digoxin tablet
bryant ranch prepack - digoxin (unii: 73k4184t59) (digoxin - unii:73k4184t59) - digoxin 125 ug - digoxin tablets are indicated for the treatment of mild to moderate heart failure in adults. digoxin tablets increase left ventricular ejection fraction and improve heart failure symptoms as evidenced by improved exercise capacity and decreased heart failure-related hospitalizations and emergency care, while having no effect on mortality. where possible, digoxin tablets should be used in combination with a diuretic and an angiotensin-converting enzyme (ace) inhibitor. digoxin tablets increase myocardial contractility in pediatric patients with heart failure. digoxin tablets are indicated for the control of ventricular response rate in adult patients with chronic atrial fibrillation. digoxin tablets are contraindicated in patients with: - ventricular fibrillation [see warnings and precautions (5.1)] - known hypersensitivity to digoxin (reactions seen include unexplained rash, swelling of the mouth, lips or throat or a difficulty in breathing). a hypersensitivity reaction to other digitalis preparations usually
digoxin solution
precision dose, inc. - digoxin (unii: 73k4184t59) (digoxin - unii:73k4184t59) - digoxin 0.05 mg in 1 ml
pms-digoxin solution
pharmascience inc - digoxin - solution - 0.05mg - digoxin 0.05mg - cardiotonic agents